Loading cancer entity…
Loading cancer entity…
Clinical trials
186 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (21)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06462183 | Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) | active not recruiting | Phase 1 | 105 | Rgenta Therapeutics IncINDUSTRY | 2 | Sep 17, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 |
| clinicaltrials |
| NCT00878163 | GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04704661 | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | active not recruiting | Phase 1 | 51 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT00588770 | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 3 | 403 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT04576091 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer | active not recruiting | Phase 1 | 7 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | active not recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05010629 | 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma | active not recruiting | Phase 2 | 32 | Glenn J. HannaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05669664 | Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers | active not recruiting | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05075980 | Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study | active not recruiting | Phase 2 | 174 | Mayo ClinicOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03942653 | Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma | active not recruiting | Phase 2 | 20 | Manish PatelOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT04895735 | MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer | active not recruiting | Phase 2 | 45 | Mayo ClinicOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT02780310 | Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma | active not recruiting | Phase 2 | 33 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT02757859 | WASH Trial: Intraoperative Lavage as a Treatment for Pancreatic Cancer | active not recruiting | N/A | 845 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT00669734 | Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05924256 | A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing | active not recruiting | Phase 2 | 88 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06115499 | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | active not recruiting | Phase 2 / Phase 3 | 10 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04209660 | Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers | active not recruiting | Phase 2 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
Data updated 13 days agoSource updated Sep 17, 2026source: clinicaltrials